Longevity Health Holdings, Inc. (XAGE) stock
XAGEOTCSoap, Detergents, Cleang Preparations, Perfumes, CosmeticsFiscal year ends December 31Also trades as XAGEW
$0.11+0.00 (0.00%)
Close on Oct 19, 2026Market cap $277.24KP/E –Yield –
Longevity Health r&d expenses
Research and development expenses are spending on new products and technology.
Longevity Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $460.91K, down 51.3% year over year. For fiscal 2025 it was $788.89K, down 25.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $788.89K | -25.2% |
| FY2024 | Dec 31, 2024 | $1.05M | -57.8% |
| FY2023 | Dec 31, 2023 | $2.50M | +13.7% |
| FY2022 | Dec 31, 2022 | $2.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $73.35K | -67.9% |
| Q1 FY2026 | Mar 31, 2026 | $55.49K | -71.8% |
| Q4 FY2025 | Dec 31, 2025 | $104.08K | -44.9% |
| Q3 FY2025 | Sep 30, 2025 | $227.99K | -31.3% |
| Q2 FY2025 | Jun 30, 2025 | $228.61K | +119.7% |
| Q1 FY2025 | Mar 31, 2025 | $196.91K | -54.1% |
| Q4 FY2024 | Dec 31, 2024 | $189.02K | -88.1% |
| Q3 FY2024 | Sep 30, 2024 | $331.81K | -59.7% |
| Q2 FY2024 | Jun 30, 2024 | $104.07K | -85.9% |
| Q1 FY2024 | Mar 31, 2024 | $429.42K | -33.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.59M | +178.6% |
| Q2 FY2023 | Jun 30, 2023 | $823.66K | – |
| Q1 FY2023 | Mar 31, 2023 | $740.33K | – |
| Q4 FY2022 | Dec 31, 2022 | $641.46K | – |
| Q3 FY2022 | Sep 30, 2022 | $570.94K | – |
See a number that looks wrong?